BRAF and Miyoshi myopathy: Along with already known NRAS and KRAS mutations, these also include BRAF mutations, which have been recently reported to occur in 4-15% of patients [4-6] and may be of potentially immediate clinical relevance because of the availability of effective BRAF inhibitors that are also being investigated in MM treatment [7-9].